Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) 3-Year RORE % : 27.80% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603882 Guangzhou Kingmed Diagnostics Group Co Ltd SHSE:603882
75 GF Score
Price ¥28.97
GF Value ¥28.10
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Guangzhou Kingmed Diagnostics Group Co 3-Year RORE %?

Guangzhou Kingmed Diagnostics Group Co SHSE:603882 +3.35% 75 3-Year RORE % is 27.80 as of Mar. 2026. GuruFocus rates SHSE:603882 with a GF Score™ of 75/100 and a GF Value™ of ¥28.10 (Fairly Valued). The stock has 7 warning signs investors should review. Among 198 Medical Diagnostics & Research companies, Guangzhou Kingmed Diagnostics Group Co ranks better than 81.31% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Guangzhou Kingmed Diagnostics Group Co's 3-Year RORE % for the quarter that ended in Mar. 2026 was 27.80%.

The industry rank for Guangzhou Kingmed Diagnostics Group Co's 3-Year RORE % or its related term are showing as below:

SHSE:603882's 3-Year RORE % is ranked better than
81.31% of 198 companies
in the Medical Diagnostics & Research industry
Industry Median: -8.425 vs SHSE:603882: 27.80

Guangzhou Kingmed Diagnostics Group Co  (SHSE:603882) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Guangzhou Kingmed Diagnostics Group Co 3-Year RORE % Related Terms


Guangzhou Kingmed Diagnostics Group Co 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Guangzhou Kingmed Diagnostics Group Co's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guangzhou Kingmed Diagnostics Group Co 3-Year RORE % Chart

Guangzhou Kingmed Diagnostics Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 46.66 21.42 -39.12 -267.33 52.24

Guangzhou Kingmed Diagnostics Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,092.00 535.90 123.69 52.24 27.80

SHSE:603882 vs TMO, DHR, IDXX: 3-Year RORE % Comparison

For the Diagnostics & Research subindustry, Guangzhou Kingmed Diagnostics Group Co's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guangzhou Kingmed Diagnostics Group Co 3-Year RORE % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Guangzhou Kingmed Diagnostics Group Co's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Guangzhou Kingmed Diagnostics Group Co's 3-Year RORE % falls into.


SHSE:603882
75GF Score
Guangzhou Kingmed Diagnostics Group Co Ltd SHSE:603882
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guangzhou Kingmed Diagnostics Group Co 3-Year RORE % Calculation

Guangzhou Kingmed Diagnostics Group Co's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.22-1.02 )/( -0.04-4.42 )
=-1.24/-4.46
=27.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 27.80 mean?
Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) has a 3-Year RORE % of 27.80 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Guangzhou Kingmed Diagnostics Group Co and its competitors. According to the industry distribution chart, Guangzhou Kingmed Diagnostics Group Co ranks #37 out of 198 companies in the Medical Diagnostics & Research industry, placing it in the top 18.7%.
Is Guangzhou Kingmed Diagnostics Group Co's 3-Year RORE % too high?
Guangzhou Kingmed Diagnostics Group Co's current 3-Year RORE % is 27.80. Based on the distribution chart, Guangzhou Kingmed Diagnostics Group Co ranks #37 out of 198 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Guangzhou Kingmed Diagnostics Group Co has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Kingmed Diagnostics Group Co's 3-Year RORE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Guangzhou Kingmed Diagnostics Group Co ranks #37 out of 198 companies for 3-Year RORE %. This places Guangzhou Kingmed Diagnostics Group Co in the top 19% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Diagnostics & Research company?
A good 3-Year RORE % depends on the Medical Diagnostics & Research industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Guangzhou Kingmed Diagnostics Group Co and its competitors. Guangzhou Kingmed Diagnostics Group Co's current 3-Year RORE % is 27.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Kingmed Diagnostics Group Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) is currently considered Fairly Valued. The stock's GF Value™ is ¥28.10, compared to a current price of ¥28.97 — trading 3.1% above its estimated fair value. The current 3-Year RORE % is 27.80. Guangzhou Kingmed Diagnostics Group Co's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Guangzhou Kingmed Diagnostics Group Co (SHSE:603882), the current 3-Year RORE % is 27.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) Overvalued in 2026?

Based on GuruFocus' analysis, Guangzhou Kingmed Diagnostics Group Co stock appears to be overvalued. The current stock price of ¥28.97 is trading 3.1% above its estimated GF Value™ of ¥28.10. GuruFocus considers Guangzhou Kingmed Diagnostics Group Co to be Fairly Valued.

Key valuation signals for SHSE:603882:

  • 3-Year RORE %: 27.80
  • GF Value™: ¥28.10 vs. price of ¥28.97 (3.1% above fair value)
  • GF Score™: 75/100 with 7 warning signs

No single metric tells the full story. See the SHSE:603882 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Guangzhou Kingmed Diagnostics Group Co Business Description

Address International Biological Island spiral three on the 10th, Guangdong Province, Guangzhou, CHN, 510000
Founded in 1994, KingMed is the largest independent clinical laboratory in China. It was listed on the Shanghai Stock Exchange in 2017. As of 2024, KingMed has 50 centralized labs and provides over 4000 test items. Over 90% of its total revenue comes from clinical diagnostics. Furthermore, KingMed has been actively investing in its cold chain logistics. Its service network covers the most intensely populated areas in China.
75GF Score

Get the complete analysis for SHSE:603882

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥28.97
Price
¥28.10
GF Value